Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

First bovine respiratory disease vaccine for newborn calves
BOVILIS® INtranasal RSP™ Live vaccine is now licensed for use in calves from birth onwards.

MSD announces only BRD vaccine that can be administered in early life. 

MSD Animal Health has announced the first bovine respiratory disease (BRD) vaccine for newborn calves.

In a press release, the manufacturer said its new BOVILIS® INtranasal RSP™ Live vaccine is now licensed for use in calves from birth onwards. 

It is the only BRD vaccine that can be administered in early life – a significant advantage given that the sooner young calves can be protected from viral BRD and the harm it causes, the better.

An MSD Animal Health spokesperson said: “BOVILISâ INtranasal RSPä Live delivers the fastest on-farm protection of all the available pneumonia vaccines, with an onset of immunity after administration for BRSV of just six days (for calves vaccinated from the day of birth onwards) and five days (for calves vaccinated from the age of one week onwards). 

“Onset of immunity after administration for Pi3V is one week after vaccination. The duration of immunity is 12 weeks for both viruses.”

BRD is caused by bovine respiratory syncytial virus (BRSV) and parainfluenza virus 3 (Pi3).

Early and fast protection against pneumonia is important. Indeed, research published in the Journal of Dairy Science shows that replacement heifers that do not suffer pneumonia while they are calves produce more than 500 kg more milk during their first lactation. 

“BOVILIS® INtranasal RSP™ Live also has significant practical usage benefits in that it can now be used on farm at the same time as other early life interventions associated with newborn calves – for example, colostrum/first milk feeding, navel management, tagging, jacketing and necessary pen movements,” the spokesperson continued.

“Additionally, BOVILIS® INtranasal RSP™ Live can be used up to six hours after mixing with the solvent, which is the longest of all the available intranasal vaccines for these pathogens. It is supplied as a farm-friendly, easy-to administer nasal suspension product that doesn’t need a specific applicator – although for maximum flexibility an easy-clean injector and nozzle kit is available for vaccinating multiple animals.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.